Skip to Content

Lisata Therapeutics Inc LSTA

Morningstar Rating
$3.55 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

LSTA is trading at a 141% premium.
Price
$3.57
Fair Value
$7.00
Uncertainty
Extreme
1-Star Price
$25.43
5-Star Price
$2.24
Economic Moat
Ddcgk
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LSTA is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$3.55
Day Range
$3.553.63
52-Week Range
$1.953.83
Bid/Ask
$3.55 / $3.59
Market Cap
$29.49 Mil
Volume/Avg
1,281 / 16,645

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
25

Valuation

Metric
LSTA
Price/Earnings (Normalized)
Price/Book Value
0.69
Price/Sales
Price/Cash Flow
Price/Earnings
LSTA

Financial Strength

Metric
LSTA
Quick Ratio
8.13
Current Ratio
8.92
Interest Coverage
Quick Ratio
LSTA

Profitability

Metric
LSTA
Return on Assets (Normalized)
−31.90%
Return on Equity (Normalized)
−35.13%
Return on Invested Capital (Normalized)
−35.16%
Return on Assets
LSTA
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
BdmplblmcGfrsk$589.6 Bil
Vertex Pharmaceuticals Inc
VRTX
BgvhrgwZknkp$126.9 Bil
Regeneron Pharmaceuticals Inc
REGN
RrzmsdgsVtvnjyh$117.2 Bil
Moderna Inc
MRNA
RbgwwrlhTkd$46.4 Bil
Alnylam Pharmaceuticals Inc
ALNY
DwtlwyfvkLvtwd$30.1 Bil
argenx SE ADR
ARGX
LgvncqrwbRqph$28.0 Bil
BioNTech SE ADR
BNTX
ZswcssrkFgt$20.6 Bil
Biomarin Pharmaceutical Inc
BMRN
PxfpvkmkSkrrsbp$16.0 Bil
United Therapeutics Corp
UTHR
PwydtmldGklpt$14.6 Bil
Incyte Corp
INCY
ZrpxqxrSsfcqfn$13.0 Bil

Sponsor Center